RxDoctor Payments Data

Nirav Gandhi, MD

Internal Medicine · Henderson, NVNPI 1881791564

Payments from drug & device makers

$6,531in general payments, 2019–2025

Across 378 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$507
  • Novartis$480
  • Novo Nordisk$444
  • GSK$332
  • Pfizer$319
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,49799%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,531 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$115,807
Medicare patients
200
Services billed
1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide57$106,612
OzempicSemaglutide28$50,720
TrulicityDulaglutide22$44,577
JardianceEmpagliflozin28$38,629
XareltoRivaroxaban23$35,520
EliquisApixaban26$27,023
Breo ElliptaFluticasone/Vilanterol14$11,013
Emgality PenGalcanezumab-Gnlm12$8,338
SymbicortBudesonide/Formoterol Fumarate13$2,892
Duloxetine Hcl78$2,504
Celecoxib28$2,324
Levothyroxine Sodium211$2,260
Silodosin19$2,102
Liothyronine Sodium60$2,095
Atorvastatin Calcium198$1,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$225$151,18979 claims
Novo NordiskOzempic$444$50,72028 claims
Boehringer IngelheimJardiance$289$38,62928 claims
Johnson & JohnsonXarelto$68$35,52023 claims
PfizerEliquis, Paxlovid$319$28,45242 claims
GSKBreo Ellipta$332$11,01314 claims
AstraZenecaSymbicort$247$2,89213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →